Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Emyria Ltd ( (AU:EMD) ) is now available.
Emyria Limited reported a strong increase in revenue from customer sales and clinical services for the half-year ended 31 December 2025, with income rising 136% to $1.55 million compared with the prior corresponding period. Despite this top-line growth, the company’s net loss widened significantly to $2.37 million, reflecting higher expenses as it scales operations and invests in its service platform.
Net tangible assets per ordinary security improved markedly to 1.28 cents from 0.31 cents a year earlier, indicating a stronger underlying balance sheet. The board did not declare or pay any dividends and has no dividend reinvestment plan in place, underscoring the company’s focus on reinvestment and capital retention as it continues to build out its clinical and commercial activities.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
More about Emyria Ltd
Emyria Limited operates in the healthcare and clinical services sector, generating revenue from customer sales and clinical services. The company focuses on delivering specialised medical offerings and related services, positioning itself within a niche segment of the broader health and life sciences market.
Average Trading Volume: 1,572,845
Technical Sentiment Signal: Hold
Current Market Cap: A$42.75M
Find detailed analytics on EMD stock on TipRanks’ Stock Analysis page.